Melanoma Cell Growth Inhibited by Novel Compound
News Jan 04, 2018 | by Laura Elizabeth Mason, Science Writer, Technology Networks
Cancer Cell Among 'Normal' Cells
Through a collaborative effort, researchers have developed a novel compound with the ability to inhibit melanoma cell growth. This research, published today in Nature Communications, could pave the way for the development of a new class of cancer therapies, with improved safety and efficacy.
The term ‘epigenetics’ is used to define the molecular processes that influence changes in gene expression, without directly affecting the original DNA sequence. The body is able to turn genes ‘on’ or ‘off’ via epigenetic changes. These changes can result in cellular modifications that can lead to the conversion of a cell from ‘normal’ to ‘cancerous’, and can also promote a tumor’s growth and resistance to treatment.
The novel compound ‘Corin’ can target specific epigenetic modifying proteins. Through this mechanism, it could be possible to significantly improve a patient’s condition, without unwanted adverse effects. The clinical use of epigenetic drugs is currently limited due to their limited therapeutic window and unexpected adverse effects. Corin’s dual-target specificity makes it an attractive inhibitor of epigenetic modifications, as it enables selective targeting of epigenetic complexes, more specifically, it inhibits cellular demethylase and deacetylase activity.
Co-corresponding author Rhoda M. Alani, MD, Boston University School of Medicine (BUSM), commented on the potential impact of their findings in a recent press release: "It is anticipated that this novel compound will have significant efficacy in human melanomas and other cancers either as a stand-alone therapy or in combination with other targeted or immune-based therapies,"
The researchers used a melanoma cell culture system to assess the efficacy of Corin, and determined that several cancer-associated activities; cellular growth, differentiation and migration, were affected in vitro. Additional experimental melanoma models demonstrated that the compound could inhibit tumor cell growth with nominal toxicity.
The team noted that the effectiveness of targeted epigenetic therapies may not be confined to the oncology field, as epigenetic changes are also known to affect the immune system.
Alani concluded: "It is expected that this study will lay the foundation for developing a new class of potent and effective cancer therapies and the development of reagents targeting epigenetic events in immune-mediated diseases as well as other epigenetically-influenced diseases."
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
Lake gives Clues to Earth's Ancient AtmosphereNews
A sample of ancient oxygen, teased out of a 1.4 billion-year-old evaporative lake deposit in Ontario, provides fresh evidence of what the Earth’s atmosphere and biosphere were like during the interval leading up to the emergence of animal life.READ MORE
Big Data Study Targets Genomic Dark Matter from Ocean Floor to Gut FloraNews
An international team led by computational biologist Fran Supek at IRB Barcelona develop a machine learning method to predict unknown gene functions of microbes.The system examines and compares ‘big data’ available on the metagenomes of human and environmental microbiomes.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018